BIOPHYTIS

BIOPHYTIS (EPA:ALBPS)

14/02/2020 08:01

Biophytis Trading will resume on February 14th, 2020 at 09:00 CET

Voir tous les communiqués de BIOPHYTIS

BIOPHYTIS (EPA:ALBPS)

14/02/2020 08:00

Biophytis successfully completes a € 3.3 million capital increase to strengthen its financing structure

Voir tous les communiqués de BIOPHYTIS

BIOPHYTIS (EPA:ALBPS)

13/02/2020 08:00

Biophytis shares trading is suspended pending a new press release

Voir tous les communiqués de BIOPHYTIS

BIOPHYTIS (EPA:ALBPS)

11/02/2020 08:00

Biophytis - Protocol Amendment of SARA-INT, a Phase 2b Clinical Trial of Sarconeos (BIO101) in Sarcopenia, Cleared by FDA and AFMPS

Voir tous les communiqués de BIOPHYTIS

BIOPHYTIS (EPA:ALBPS)

27/01/2020 08:00

Biophytis SARA-INT Phase 2b study, evaluating the efficacy of Sarconeos (BIO101) in sarcopenia, has now achieved over 50% patient recruitment

Voir tous les communiqués de BIOPHYTIS

BIOPHYTIS (EPA:ALBPS)

10/01/2020 19:31

Biophytis announces the issuance of a €3 million tranche of ORNANEBSA

Voir tous les communiqués de BIOPHYTIS

BIOPHYTIS (EPA:ALBPS)

02/01/2020 18:00

Biophytis has appointed Evelyne Nguyen as CFO and Strengthens Senior Management Team

Voir tous les communiqués de BIOPHYTIS

BIOPHYTIS (EPA:ALBPS)

16/12/2019 08:00

Biophytis Receives FDA Approval to Proceed with the MYODA Program for Clinical Development of Sarconeos (BIO101) in Patients with Duchenne Muscular Dystrophy (DMD)

Voir tous les communiqués de BIOPHYTIS

BIOPHYTIS (EPA:ALBPS)

12/12/2019 18:00

Biophytis to attend Biotech Showcase™ 2020 in San Francisco, USA

Voir tous les communiqués de BIOPHYTIS

BIOPHYTIS (EPA:ALBPS)

09/12/2019 08:00

Biophytis Presents Preliminary Analysis of SARA-OBS study at the 12th Annual Congress of The Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) in Berlin, Germany

Voir tous les communiqués de BIOPHYTIS

1
2
3
4
5
6
7
8
9
10
»